Sign in

ENLV on Nasdaq

Enlivex

Logo: enlivex.com3

Enlivex is an Israeli drug company, focused on Cell Immunotherapy, based in Ness Ziona, founded in 2005.1 Its shares trade on Nasdaq under the symbol ENLV.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$1.2BNet income, fiscal 20254
2005Founded1

Compare with another stock.

  • TickerENLV on Nasdaq1
  • Industrybiotechnology1
  • HeadquartersNess Ziona1
  • Founded inIsrael1
  • Websitewww.enlivex.com
  • Legal formlimited company, public company1
  • Listed onNasdaq (ENLV), Tel Aviv Stock Exchange (ENLV)1
  • Incorporated inIsrael5
  • Business address37 Dereh Menachem Begin St., 15Th Floor, Tel Aviv5
  • Filer categoryNon-accelerated filer5

See how the biggest companies compare on our leaderboards

Enlivex image from its website
Image: enlivex.com6

Enlivex R&D changed its name to Enlivex Therapeutics Ltd., and upon consummation of the Merger, to Enlivex Therapeutics R&D Ltd.7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

63.9%Return on equity4
-$10.5MFree cash flow4

Financial statements

Operating income891011124-$15.0M in 2025+184% since 2018
-$30.0M-$20.0M-$10.0M02018: -$5.3M-$5.3M20182019: -$8.6M-$8.6M2019+63%2020: -$9.8M-$9.8M2020+14%2021: -$19.3M-$19.3M2021+97%2022: -$25.8M-$25.8M2022+34%2023: -$29.4M-$29.4M2023+14%2024: -$15.9M-$15.9M2024−46%2025: -$15.0M-$15.0M2025−5%
Net income891011124$1.2B in 2025
-$500.0M0$500.0M$1.0B$1.5B2018: -$4.2M-$4.2M20182019: -$9.4M-$9.4M2019+121%2020: -$11.8M-$11.8M2020+26%2021: -$14.5M-$14.5M2021+22%2022: -$31.1M-$31.1M2022+115%2023: -$29.1M-$29.1M2023−6%2024: -$15.0M-$15.0M2024−48%2025: $1.2B$1.2B2025
Fiscal year20182019202020212022202320242025
Research and development$4.0M8$5.6M9$6.1M10$12.9M11$18.7M12$19.0M4$10.6M4$9.2M4
Operating expenses$19.3M11$25.8M12$29.4M4$15.9M4$15.0M4
Operating income-$5.3M8-$8.6M9-$9.8M10-$19.3M11-$25.8M12-$29.4M4-$15.9M4-$15.0M4
Income before tax$14.5M9-$29.1M4-$15.0M4$1.6B4
Income tax-$4.0K13$382.6M4
Net income-$4.2M8-$9.4M9-$11.8M10-$14.5M11-$31.1M12-$29.1M4-$15.0M4$1.2B4
Earnings per share-$0.9010-$0.8111-$1.6912-$1.564-$0.734$27.044
Earnings per share (diluted)-$0.9010-$0.8111-$1.6912-$1.564-$0.734$25.484
Shares (weighted, basic)17.9M shares1118.4M shares1218.6M shares420.5M shares445.7M shares4
Shares (weighted, diluted)17.9M shares1118.4M shares1218.6M shares420.5M shares448.5M shares4

Compare Enlivex with another company

Corporate structure

Enlivex sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Enlivex

  • Enlivex Ness Ziona

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Enlivex reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.7M4 Dec 31, 2025$3.6M4 Dec 31, 2024+1.1%
Accumulated depreciation$3.3M4 Dec 31, 2025$3.0M4 Dec 31, 2024+10.2%
Property and equipment, net$361.0K4 Dec 31, 2025$625.0K4 Dec 31, 2024−42.2%
Operating-lease assets (leased space)$577.0K4 Dec 31, 2025$528.0K4 Dec 31, 2024+9.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.9M4 Dec 31, 2025$3.3M4 Dec 31, 2024−42.6%
Marketable securities, current$198.0K4 Dec 31, 2024$5.1M12 Dec 31, 2023−96.1%

Leadership

Who has led Enlivex, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Oren Hershkovitz2026–now

Chief financial officer

  1. Shachar Shlosberger2026–now
2010201520202025
Board members and other officers (5)

Former names

  • Enlivex Therapeutics Ltd.Mar 27, 2019 to Feb 10, 20265
  • Bioblast Pharma Ltd.Oct 24, 2016 to Mar 18, 20195
  • BIO BLAST PHARMA LTD.Feb 7, 2014 to Sep 12, 20165

Timeline

  1. Mar 18, 2026New chief executive Oren Hershkovitz becomes CEO15
  2. 2005Founded Founded in Israel1

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.35) a share, on Nov 14, 2025.22

Drug trials and FDA: coming up

  1. Feb 2027Phase 2 trial readout expected Phase 2 trial of Allocetra in Primary Knee Osteoarthritis: primary completion expected Feb 2027 (ClinicalTrials.gov NCT07580716).23

Drug trials and FDA: recently

  1. Mar 15, 2026Phase 1/2 trial completed Phase 1/2 trial of Allocetra in Osteoarthritis, Knee: primary completion Mar 15, 2026, no results posted yet (ClinicalTrials.gov NCT06233474).24

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

188 filings to the SEC since October 2021: 5 annual reports, 7 insider forms, 5 large holders, 171 other. The latest 20:

  1. Oct 2, 20266-K/A AMENDMENT NO. 2 TO FORM 6-K EDGAR
  2. Oct 1, 20266-K/A CURRENT REPORT EDGAR
  3. Sep 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 25, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Aug 17, 2026424B3 PROSPECTUS EDGAR
  7. Aug 13, 2026EFFECT EDGAR
  8. Aug 13, 2026SCHEDULE 13G EDGAR
  9. Aug 11, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Aug 6, 2026F-3 REGISTRATION STATEMENT EDGAR
  11. Jul 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  12. Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Jul 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Jul 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Jul 20, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Jul 13, 20266-K EDGAR
  17. Jul 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jun 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Jun 22, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  20. May 28, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR

The 188 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Enlivex is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREnlivex Ltd.2
  • CIK0001596812
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company7
  • Incorporated inIsrael7
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address37 Dereh Menachem Begin St., 15Th Floor, Tel Aviv, Israel2
  • Phone972 (0) 3 73266162
  • Shares outstanding237,381,498 shares as of Dec 31, 20257
  • AuditorYarel + Partners, Tel-Aviv, Israel PCAOB ID 1024; it also attests to the company’s internal control over financial reporting7
  • On EDGAR sinceFeb 7, 20142
  • Filings414 in all: 6-K (280), CORRESP (13), UPLOAD (13), 20-F (12), SC 13G (11), 424B5 (10), SC 13G/A (10), EFFECT (9)2
    All 26 form types

    F-1/A (9), F-3 (8), 3 (7), 424B3 (6), 6-K/A (4), S-8 (4), SCHEDULE 13G/A (3), 20-F/A (2), D (2), F-1 (2), FWP (2), 424B4 (1), 8-A12B (1), CERTNAS (1), F-3MEF (1), RW (1), SC 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Mar 25, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, par value NIS 0.40 per shareENLVNasdaq

From the cover page of the 20-F filed Mar 25, 2026 (Section 12(b) of the Exchange Act).7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteEnlivex logo
  4. 4
  5. 5
  6. 6
    Company websiteEnlivex photo
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26